605 related articles for article (PubMed ID: 24300213)
21. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.
Sánchez-López E; Ettcheto M; Egea MA; Espina M; Cano A; Calpena AC; Camins A; Carmona N; Silva AM; Souto EB; García ML
J Nanobiotechnology; 2018 Mar; 16(1):32. PubMed ID: 29587747
[TBL] [Abstract][Full Text] [Related]
22. Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia.
Wang ZL; Cheng SM; Ma MM; Ma YP; Yang JP; Xu GL; Liu XF
Neurosci Lett; 2008 Nov; 446(1):30-5. PubMed ID: 18822350
[TBL] [Abstract][Full Text] [Related]
23. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration.
Wen Z; Yan Z; Hu K; Pang Z; Cheng X; Guo L; Zhang Q; Jiang X; Fang L; Lai R
J Control Release; 2011 Apr; 151(2):131-8. PubMed ID: 21362449
[TBL] [Abstract][Full Text] [Related]
24. Intranasal bFGF-induced progenitor cell proliferation and neuroprotection after transient focal cerebral ischemia.
Ma YP; Ma MM; Cheng SM; Ma HH; Yi XM; Xu GL; Liu XF
Neurosci Lett; 2008 May; 437(2):93-7. PubMed ID: 18436379
[TBL] [Abstract][Full Text] [Related]
25. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease.
Wong LR; Ho PC
J Pharm Pharmacol; 2018 Jan; 70(1):59-69. PubMed ID: 29034965
[TBL] [Abstract][Full Text] [Related]
26. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration.
Gao X; Tao W; Lu W; Zhang Q; Zhang Y; Jiang X; Fu S
Biomaterials; 2006 Jun; 27(18):3482-90. PubMed ID: 16510178
[TBL] [Abstract][Full Text] [Related]
27. Preparation of surface multiple-coated polylactide acid drug-loaded nanoparticles for intranasal delivery and evaluation on its brain-targeting efficiency.
Bian J; Yuan Z; Chen X; Gao Y; Xu C; Shi J
Drug Deliv; 2016; 23(1):269-76. PubMed ID: 24845477
[TBL] [Abstract][Full Text] [Related]
28. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
29. The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain.
Zhang L; Han L; Qin J; Lu W; Wang J
Pharm Res; 2013 Oct; 30(10):2560-72. PubMed ID: 23615859
[TBL] [Abstract][Full Text] [Related]
30. Intranasal therapeutic strategies for management of Alzheimer's disease.
Sood S; Jain K; Gowthamarajan K
J Drug Target; 2014 May; 22(4):279-94. PubMed ID: 24404923
[TBL] [Abstract][Full Text] [Related]
31. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system.
Wu D; Song BW; Vinters HV; Pardridge WM
J Drug Target; 2002 May; 10(3):239-45. PubMed ID: 12075825
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the safety and brain-related tissues distribution characteristics of TAT-HaFGF via intranasal administration.
Xu J; Xiang Q; Su J; Yang P; Zhang Q; Su Z; Xiao F; Huang Y
Biol Pharm Bull; 2014; 37(7):1149-57. PubMed ID: 24989006
[TBL] [Abstract][Full Text] [Related]
34. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology.
Mittal G; Carswell H; Brett R; Currie S; Kumar MN
J Control Release; 2011 Mar; 150(2):220-8. PubMed ID: 21111014
[TBL] [Abstract][Full Text] [Related]
35. GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease.
Huang M; Hu M; Song Q; Song H; Huang J; Gu X; Wang X; Chen J; Kang T; Feng X; Jiang D; Zheng G; Chen H; Gao X
ACS Nano; 2015 Nov; 9(11):10801-16. PubMed ID: 26440073
[TBL] [Abstract][Full Text] [Related]
36. Effect of basic fibroblast growth factor on hippocampal cholinergic neurons in a rodent model of ischaemic encephalopathy.
Ye J; Lin H; Mu J; Cui X; Ying H; Lin M; Wu L; Weng J; Lin X
Basic Clin Pharmacol Toxicol; 2010 Dec; 107(6):931-9. PubMed ID: 20618306
[TBL] [Abstract][Full Text] [Related]
37. Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer's disease: pharmaceutical, biological, and toxicological studies.
Elnaggar YS; Etman SM; Abdelmonsif DA; Abdallah OY
Int J Nanomedicine; 2015; 10():5459-73. PubMed ID: 26346130
[TBL] [Abstract][Full Text] [Related]
38. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice.
Shi J; Perry G; Berridge MS; Aliev G; Siedlak SL; Smith MA; LaManna JC; Friedland RP
J Nucl Med; 2002 Aug; 43(8):1044-51. PubMed ID: 12163630
[TBL] [Abstract][Full Text] [Related]
39. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
[TBL] [Abstract][Full Text] [Related]
40. Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity.
Elnaggar YS; Etman SM; Abdelmonsif DA; Abdallah OY
J Pharm Sci; 2015 Oct; 104(10):3544-56. PubMed ID: 26147711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
